STOCK TITAN
  1. Home
  2. News
  3. TARA

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Protara Therapeutics to present at H.C. Wainwright Conference
Positive
  • None.
Negative
  • None.

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.

The live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement for patients dependent on parenteral nutrition. For more information, visit www.protaratx.com.

Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836


Stock TARA logo
Protara Therapeutics Inc

NASDAQ:TARA

TARA Rankings

#4939 Ranked by Market Cap
#4923 Ranked by Stock Gains
N/A Ranked by Dividends

TARA Latest News

Apr 5, 2024
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Apr 5, 2024
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
Apr 5, 2024
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Mar 13, 2024
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 28, 2024
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

TARA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
New York

About TARA

protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.